These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20449785)

  • 21. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
    Bárcena R; Del Campo S; Moraleda G; Casanovas T; Prieto M; Buti M; Moreno JM; Cuervas V; Fraga E; De la Mata M; Otero A; Delgado M; Loinaz C; Barrios C; Dieguez ML; Mas A; Sousa JM; Herrero JI; Muñoz R; Avilés JF; Gonzalez A; Rueda M
    Transplant Proc; 2005 Nov; 37(9):3960-2. PubMed ID: 16386596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.
    Tseng KC; Cheng PN; Wu IC; Chang CK; Chou AL; Liu WC; Chang TT
    Hepatogastroenterology; 2009; 56(91-92):813-8. PubMed ID: 19621708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
    Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
    Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Lin XH; Si CW; Yu YY; Li J; Chen XY; Ren XM; Liu P; Zhang SL; Kang XP
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):898-901. PubMed ID: 17196132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre.
    Giannousis IP; Papatheodoridis GV; Deutsch MJ; Manolakopoulos SG; Manesis EK; Koskinas JS; Archimandritis AJ
    Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):172-9. PubMed ID: 19738477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population.
    Jung CW; Tan J; Tan N; Kuo MN; Ashok A; Eells SJ; Miller LG
    J Gastroenterol Hepatol; 2010 Feb; 25(2):369-75. PubMed ID: 19929923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
    Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir.
    Ha M; Zhang G; Diao S; Lin M; Sun L; She H; Kuan C; Shen L; Huang C; Shen W; Huang Z
    Arch Virol; 2012 Feb; 157(2):285-90. PubMed ID: 22080196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden.
    Torre F; Basso M; Giannini EG; Feasi M; Boni S; Grasso A; De Leo P; Dodi F; Marazzi MG; Azzola E; Bartolacci V; Percario G; Beltrame A; Borro P; Picciotto A;
    J Med Virol; 2009 Nov; 81(11):1882-6. PubMed ID: 19774694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
    Zhao H; Li J; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL; Si CW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):282-4. PubMed ID: 17971947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting.
    Heidrich B; Cetindere A; Beyaz M; Stahmeyer JT; Basaran MM; Braynis B; Raupach R; Bremer B; Manns MP; Wedemeyer H; Bastürk M
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1090-7. PubMed ID: 25076065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
    Zeng M; Mao Y; Yao G; Wang H; Hou J; Wang Y; Ji BN; Chang CN; Barker KF
    Hepatology; 2006 Jul; 44(1):108-16. PubMed ID: 16799983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Xu Z; Chen LB; Cao H; Shu X; Xu QH; Li G; Xie QF
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):224-6. PubMed ID: 21186534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.